The Breast · 2021 · 26 citations · 22 references
MedicineOncologyRadiation OncologyCancer PharmacologyMolecular OncologyPalliative OncologyBreast Cancer PharmacotherapyBreast Cancer RadiotherapyMetastatic Breast CancerPalliative RadiotherapyRadiation TherapyToxicity ManagementAdjuvant Cdk4/6 Inhibitor TherapyCyclin-dependent Kinase 4/6 InhibitorsCyclin-dependent Kinase 6 InhibitorsLocal Control AssessmentMetastatic Breast Cancer TreatmentPain Response AssessmentPalliative Radiotherapy ToxicityTherapeutic Cyclin-dependent Kinase Inhibition
INTRODUCTION: Cyclin-dependent kinase (CDK)4/6 inhibitor is a first-line therapy for metastatic ER+/HER2-breast cancer. However, there are limited data on safety of combined radiotherapy (RT) and CDK4/6 inhibition. METHODS: We conducted a retrospective study of women with metastatic breast cancer who received palliative RT within 14 days of CDK4/6 inhibitor use. The primary endpoint was toxicity per Common Terminology Criteria for Adverse Events v5. Secondary endpoints were pain response and local control based on clinical assessment and imaging. RESULTS: Thirty patients underwent 36 RT courses with palbociclib (n = 34 courses, 94.4%) or abemaciclib (n = 2, 5.6%). RT was delivered before, concurrently or after CDK4/6 inhibitors in 7 (19.4%), 8 (22.2%), and 21 (58.3%) of cases with median 3.5 days from RT to closest CDK4/6 inhibitor administration. Median RT dose was 30Gy (range 8-40.05Gy). Treated sites included brain (n = 5, 11.6%), spine (n = 19, 44.2%), pelvis (n = 9, 20.9%), other bony sites (n = 6, 14.0%) and others (n = 4, 9.3%). No acute grade ≥3 non-hematologic toxicity occurred. No increased hematologic toxicity was attributable to RT with grade 3 hematologic toxicities rates 16.7%, 0%, and 6.7% before, during, and 2 weeks after RT completion. All but one patient (29/30) achieved symptom relief. Local control rates were 94.4%, 91.7% at 6 and 12 months. CONCLUSIONS: The use of RT within 2 weeks of CDK4/6 inhibitors had low acceptable toxicity and high efficacy, suggesting that it is safe for palliation of metastatic breast cancer.
22
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine · 2016 · 2.9K citations
Medicine, Oncology, Pharmacology +17
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +16
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel, Molly J. DeCristo, April C. Watt et al. · Nature · 2017 · 1.5K citations · Full text
Medicine, Cancer Biology, Oncology +12
Richard S. Finn, Judy Dering, Dylan Conklin et al. · Breast Cancer Research · 2009 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17